speb/financial-data huggingface dataset:
GSK.L cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -6000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -317000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Research And Development: 1689000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 10016000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Sale Of Business: 120000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Sale Of Intangibles: 36000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 5000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Selling General And Administration: 2239000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Share Issued: 4315407340.00
GSK.L cash_flow (quarterly, 2025-09-30) — Short Term Debt Issuance: -76000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Short Term Debt Payments: -13000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 16148000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -7834000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
GSK.L income_statement (quarterly, 2025-09-30) — Tax Provision: 312000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.13
GSK.L balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 367000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Taxes Refund Paid: -298000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Assets: 61339000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 16148000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Debt: 17750000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 15752000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Total Expenses: 5954000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 45587000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 43497000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 24253000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 2593000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 324000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 289069844.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Working Capital: -3492000000.00
GSK.L income_statement (annual, 2025-12-31) — +Operating Expense: 15312000000.00
GSK.L income_statement (quarterly, 2025-12-31) — +Operating Expense: 4455000000.00
GSK.L income_statement (annual, 2025-12-31) — +Total Revenue: 32667000000.00
GSK.L income_statement (quarterly, 2025-12-31) — +Total Revenue: 8618000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Accounts Payable: 3535000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 3535000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Accounts Receivable: 5913000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 5913000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -10892000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -10892000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 3498000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 3498000000.00
GSK.L cash_flow (annual, 2025-12-31) — Amortization Cash Flow: 1258000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Assets Held For Sale Current: 300000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 300000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 790000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Available For Sale Securities: 790000000.00
GSK.L income_statement (annual, 2025-12-31) — Basic Average Shares: 4051000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Basic Average Shares: 4019000000.00
GSK.L income_statement (annual, 2025-12-31) — Basic EPS: 1.41
GSK.L income_statement (quarterly, 2025-12-31) — Basic EPS: 0.16
GSK.L cash_flow (annual, 2025-12-31) — Beginning Cash Position: 3403000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 2759000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 531000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 531000000.00
GSK.L cash_flow (annual, 2025-12-31) — Capital Expenditure: -2985000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -1025000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 830000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 830000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Capital Stock: 1349000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Capital Stock: 1349000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 3150000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 3150000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 3159000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 3159000000.00
GSK.L cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -2564000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: -646000000.00
GSK.L cash_flow (annual, 2025-12-31) — Change In Inventory: -140000000.00
GSK.L cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -1139000000.00
GSK.L cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: 465000000.00
GSK.L cash_flow (annual, 2025-12-31) — Change In Payable: 474000000.00
GSK.L cash_flow (annual, 2025-12-31) — Change In Receivables: -1097000000.00
GSK.L cash_flow (annual, 2025-12-31) — Change In Working Capital: -1437000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 588000000.00
GSK.L cash_flow (annual, 2025-12-31) — Changes In Cash: -177000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Changes In Cash: 489000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Common Stock: 1349000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Common Stock: 1349000000.00
GSK.L cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -2564000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Common Stock Dividend Paid: -646000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Common Stock Equity: 16377000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 16377000000.00
GSK.L cash_flow (annual, 2025-12-31) — Common Stock Issuance: 15000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 1000000.00
GSK.L cash_flow (annual, 2025-12-31) — Common Stock Payments: -1377000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -252000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Construction In Progress: 2511000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 2511000000.00
GSK.L income_statement (annual, 2025-12-31) — Cost Of Revenue: 9017000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2657000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Current Assets: 17510000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Current Assets: 17510000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 137000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 137000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Current Debt: 2875000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Current Debt: 2875000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 3012000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 3012000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Current Liabilities: 21391000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 21391000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Current Provisions: 938000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Current Provisions: 938000000.00
GSK.L cash_flow (annual, 2025-12-31) — Deferred Tax: 1112000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Deferred Tax: 223000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Defined Pension Benefit: 1115000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Defined Pension Benefit: 1115000000.00
GSK.L cash_flow (annual, 2025-12-31) — Depreciation: 1056000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Depreciation: -1664000000.00
GSK.L cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 2314000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: -406000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Derivative Product Liabilities: 67000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Derivative Product Liabilities: 67000000.00
GSK.L income_statement (annual, 2025-12-31) — Diluted Average Shares: 4117000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 4086000000.00
GSK.L income_statement (annual, 2025-12-31) — Diluted EPS: 1.39
GSK.L income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.16
GSK.L income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 5716000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 636000000.00
GSK.L cash_flow (annual, 2025-12-31) — Dividends Received Cfi: 87000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Dividends Received Cfi: 70000000.00
GSK.L income_statement (annual, 2025-12-31) — EBIT: 8088000000.00
GSK.L income_statement (quarterly, 2025-12-31) — EBIT: 1124000000.00
GSK.L income_statement (annual, 2025-12-31) — EBITDA: 10402000000.00
GSK.L income_statement (quarterly, 2025-12-31) — EBITDA: 1124000000.00
GSK.L cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -19000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -41000000.00
GSK.L cash_flow (annual, 2025-12-31) — End Cash Position: 3207000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — End Cash Position: 3207000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Financial Assets: 0.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Financial Assets: 0.00
GSK.L balance_sheet (annual, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 263000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 263000000.00
GSK.L cash_flow (annual, 2025-12-31) — Financing Cash Flow: -3685000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -856000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Finished Goods: 1617000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Finished Goods: 1617000000.00
GSK.L cash_flow (annual, 2025-12-31) — Free Cash Flow: 4756000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 1253000000.00
GSK.L cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -4000000.00
GSK.L cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of Business: 9000000.00
GSK.L cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: -49000000.00
GSK.L income_statement (annual, 2025-12-31) — General And Administrative Expense: 9088000000.00
GSK.L income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 2639000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Goodwill: 7018000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Goodwill: 7018000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 23766000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 23766000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 5913000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 5913000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Gross PPE: 20940000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Gross PPE: 20940000000.00
GSK.L income_statement (annual, 2025-12-31) — Gross Profit: 23650000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Gross Profit: 5961000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Hedging Assets Current: 121000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Hedging Assets Current: 121000000.00
GSK.L income_statement (annual, 2025-12-31) — Interest Expense: 687000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Interest Expense: 174000000.00
GSK.L income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 687000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 174000000.00
GSK.L income_statement (annual, 2025-12-31) — Interest Income: 56000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Interest Income: -74000000.00
GSK.L income_statement (annual, 2025-12-31) — Interest Income Non Operating: 56000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: -74000000.00
GSK.L cash_flow (annual, 2025-12-31) — Interest Paid Cff: -679000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Interest Paid Cff: -295000000.00
GSK.L cash_flow (annual, 2025-12-31) — Interest Received Cfi: 154000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Interest Received Cfi: 37000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Inventory: 5924000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Inventory: 5924000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Invested Capital: 33267000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Invested Capital: 33267000000.00
GSK.L cash_flow (annual, 2025-12-31) — Investing Cash Flow: -4233000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -933000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 1053000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 1053000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Investmentsin Associatesat Cost: 89000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Investmentsin Associatesat Cost: 89000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK.L cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 15000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 1000000.00
GSK.L cash_flow (annual, 2025-12-31) — Issuance Of Debt: 3194000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 552000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Land And Improvements: 6157000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 6157000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 693000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 693000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Long Term Debt: 14015000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 14015000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14708000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14708000000.00
GSK.L cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 1979000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
GSK.L cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -1400000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 2000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 89000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 89000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Long Term Provisions: 610000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 610000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 11735000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 11735000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Minority Interest: -421000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Minority Interest: -421000000.00
GSK.L income_statement (annual, 2025-12-31) — Minority Interests: -573000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Minority Interests: -91000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -1639000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -31000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -1362000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -251000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Net Debt: 13740000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Net Debt: 13740000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Income: 5716000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Income: 636000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 5716000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 636000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 6289000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 727000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 5716000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 636000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 5716000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 636000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 6289000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 727000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 6289000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 727000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -1522000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -449000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Interest Income: -633000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Interest Income: -250000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 11000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 0.00
GSK.L cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 1506000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 548000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 579000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 2000000.00
GSK.L income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -633000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -250000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 46000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -25000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Net PPE: 10048000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Net PPE: 10048000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -1324000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -560000000.00
GSK.L cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: 927000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Net Short Term Debt Issuance: 546000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -7389000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -7389000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Non Current Accrued Expenses: 6000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Non Current Accrued Expenses: 6000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 121000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 121000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 6520000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 6520000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 291000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 291000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1687000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1687000000.00
GSK.L income_statement (annual, 2025-12-31) — Normalized EBITDA: 10707000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 1124000000.00
GSK.L income_statement (annual, 2025-12-31) — Normalized Income: 5975173760.30
GSK.L income_statement (quarterly, 2025-12-31) — Normalized Income: 636000000.00
GSK.L cash_flow (annual, 2025-12-31) — Operating Cash Flow: 7741000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 2278000000.00
GSK.L income_statement (annual, 2025-12-31) — Operating Income: 8338000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Operating Income: 1506000000.00
GSK.L income_statement (annual, 2025-12-31) — Operating Revenue: 32667000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Operating Revenue: 8618000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 4012550322.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 4012550322.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 1348000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 1348000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Equity Interest: -282000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: -282000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 16748000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 16748000000.00
GSK.L cash_flow (annual, 2025-12-31) — Other Non Cash Items: 568000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 185000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 5385000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 5385000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Payable: 438000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Payable: 438000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Properties: 6000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Properties: 6000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Receivables: 662000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Receivables: 662000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 9000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 9000000.00
GSK.L income_statement (annual, 2025-12-31) — Other Special Charges: 232000000.00
GSK.L income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (annual, 2025-12-31) — Payables: 4471000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Payables: 4471000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 138000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 138000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Prepaid Assets: 385000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 385000000.00
GSK.L income_statement (annual, 2025-12-31) — Pretax Income: 7401000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Pretax Income: 950000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Properties: 0.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
GSK.L cash_flow (annual, 2025-12-31) — Purchase Of Business: -1828000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -82000000.00
GSK.L cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -1637000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -452000000.00
GSK.L cash_flow (annual, 2025-12-31) — Purchase Of PPE: -1348000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -573000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Raw Materials: 608000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Raw Materials: 608000000.00
GSK.L income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 9017000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2657000000.00
GSK.L income_statement (annual, 2025-12-31) — Reconciled Depreciation: 2314000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: -406000000.00
GSK.L cash_flow (annual, 2025-12-31) — Repayment Of Debt: -1688000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -4000000.00
GSK.L cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -1377000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -252000000.00
GSK.L income_statement (annual, 2025-12-31) — Research And Development: 7525000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Research And Development: 2350000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Restricted Cash: 247000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 247000000.00
GSK.L income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 581000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Retained Earnings: 10209000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 10209000000.00
GSK.L cash_flow (annual, 2025-12-31) — Sale Of Business: 189000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Sale Of Business: 51000000.00
GSK.L cash_flow (annual, 2025-12-31) — Sale Of Intangibles: 115000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Sale Of Intangibles: 3000000.00
GSK.L cash_flow (annual, 2025-12-31) — Sale Of PPE: 24000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 13000000.00
GSK.L income_statement (annual, 2025-12-31) — Selling General And Administration: 9088000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Selling General And Administration: 2639000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Share Issued: 4315445026.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Share Issued: 4315445026.00
GSK.L cash_flow (annual, 2025-12-31) — Short Term Debt Issuance: 1215000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Short Term Debt Issuance: 552000000.00
GSK.L cash_flow (annual, 2025-12-31) — Short Term Debt Payments: -288000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Short Term Debt Payments: -6000000.00
GSK.L income_statement (annual, 2025-12-31) — Special Income Charges: -813000000.00
GSK.L cash_flow (annual, 2025-12-31) — Stock Based Compensation: 374000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Stockholders Equity: 16377000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 16377000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Tangible Book Value: -7389000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -7389000000.00
GSK.L income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -45826239.70
GSK.L income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
GSK.L income_statement (annual, 2025-12-31) — Tax Provision: 1112000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Tax Provision: 223000000.00
GSK.L income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.15
GSK.L income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.23
GSK.L balance_sheet (annual, 2025-12-31) — Taxes Receivable: 799000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 799000000.00
GSK.L cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -1202000000.00
GSK.L cash_flow (quarterly, 2025-12-31) — Taxes Refund Paid: -411000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Assets: 61118000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Assets: 61118000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Capitalization: 30392000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 30392000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Debt: 17720000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Debt: 17720000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 15956000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 15956000000.00
GSK.L income_statement (annual, 2025-12-31) — Total Expenses: 24329000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Total Expenses: 7112000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 45162000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 45162000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 43608000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 43608000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 23771000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 23771000000.00
GSK.L income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 7932000000.00
GSK.L income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 1100000000.00
GSK.L income_statement (annual, 2025-12-31) — Total Other Finance Cost: 2000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Total Tax Payable: 498000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 498000000.00
GSK.L income_statement (annual, 2025-12-31) — Total Unusual Items: -305000000.00
GSK.L income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -305000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 896000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 896000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 302894704.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 302894704.00
GSK.L balance_sheet (annual, 2025-12-31) — Work In Process: 3699000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Work In Process: 3699000000.00
GSK.L balance_sheet (annual, 2025-12-31) — Working Capital: -3881000000.00
GSK.L balance_sheet (quarterly, 2025-12-31) — Working Capital: -3881000000.00
GSK.L income_statement (quarterly, 2026-03-31) — +Operating Expense: 3461000000.00
GSK.L income_statement (quarterly, 2026-03-31) — +Total Revenue: 7629000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 14335000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 7756000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 3506000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 138000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Basic Average Shares: 4023000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Basic EPS: 0.43
GSK.L cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 3250000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -443000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Capital Stock: 1349000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 3442000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 3443000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -643000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -1082000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Changes In Cash: -53000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Common Stock: 1349000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Common Stock Dividend Paid: -643000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 17852000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 8000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -326000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1875000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Current Assets: 17761000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 5044000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 22429000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Current Provisions: 908000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Deferred Tax: 305000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Depreciation: 463000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 463000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 56000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 4074000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.43
GSK.L income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 1737000000.00
GSK.L income_statement (quarterly, 2026-03-31) — EBIT: 2311000000.00
GSK.L income_statement (quarterly, 2026-03-31) — EBITDA: 2774000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 2000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — End Cash Position: 3199000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Financial Assets: 19000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 272000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 698000000.00
GSK.L income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 2119000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Goodwill: 7287000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 25425000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Gross PPE: 10038000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Gross Profit: 5754000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 86000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Interest Expense: 167000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 167000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Interest Income: 22000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 22000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Interest Paid Cff: -85000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Interest Received Cfi: 45000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Inventory: 6157000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Invested Capital: 17852000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -1466000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 8000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 1202000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 14012000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 0.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 99000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 579000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Minority Interest: -430000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Minority Interests: -102000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -1166000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -318000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Income: 1737000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 1737000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 1839000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1737000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1737000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 1839000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 1839000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -160000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Interest Income: -145000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 9000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 1182000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 0.00
GSK.L income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -145000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: 1703000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Net PPE: 10038000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -194000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Net Short Term Debt Issuance: 1182000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -7573000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 6307000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 292000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1695000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 2774000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Normalized Income: 1737000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 1141000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Operating Income: 2293000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Operating Revenue: 7629000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 4020267166.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 1395000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 18138000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Investments: 859000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 145000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 2361000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 6318000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Properties: 10038000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 1000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Payables: 14890000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Pretax Income: 2144000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -1414000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -222000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -221000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1875000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 463000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -20000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -326000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Research And Development: 1692000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 11590000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Sale Of Business: 248000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Sale Of Intangibles: 62000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Sale Of PPE: 27000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2119000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Share Issued: 4316179781.00
GSK.L cash_flow (quarterly, 2026-03-31) — Short Term Debt Issuance: 1202000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Short Term Debt Payments: -20000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 17852000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -7573000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
GSK.L income_statement (quarterly, 2026-03-31) — Tax Provision: 305000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.14
GSK.L balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 181000000.00
GSK.L cash_flow (quarterly, 2026-03-31) — Taxes Refund Paid: -209000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Assets: 62869000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 17852000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Debt: 19056000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 17422000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Total Expenses: 5336000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 45447000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 45108000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 23018000000.00
GSK.L income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 2293000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 555000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 66000000.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 295912615.00
GSK.L balance_sheet (quarterly, 2026-03-31) — Working Capital: -4668000000.00
GSKR.V income_statement (annual, 2022-12-31) — +Operating Expense: 1664174.00
GSKR.V income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
GSKR.V balance_sheet (annual, 2022-12-31) — Accounts Receivable: 71501.00
GSKR.V income_statement (annual, 2022-12-31) — Basic Average Shares: 33273567.00
GSKR.V income_statement (annual, 2022-12-31) — Basic EPS: -0.04
GSKR.V cash_flow (annual, 2022-12-31) — Beginning Cash Position: 284202.00
GSKR.V balance_sheet (annual, 2022-12-31) — Capital Stock: 11286576.00
GSKR.V balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 1253348.00
GSKR.V balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 1253348.00
GSKR.V balance_sheet (annual, 2022-12-31) — Cash Financial: 1253348.00
GSKR.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 2502970.00
GSKR.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -1533824.00
GSKR.V cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 97195.00
GSKR.V cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 37276.00
GSKR.V cash_flow (annual, 2022-12-31) — Change In Receivables: -2670.00
GSKR.V cash_flow (annual, 2022-12-31) — Change In Working Capital: 131801.00
GSKR.V cash_flow (annual, 2022-12-31) — Changes In Cash: 969146.00
GSKR.V balance_sheet (annual, 2022-12-31) — Common Stock: 11286576.00
GSKR.V balance_sheet (annual, 2022-12-31) — Common Stock Equity: 1197770.00
GSKR.V cash_flow (annual, 2022-12-31) — Common Stock Issuance: 2584435.00
GSKR.V balance_sheet (annual, 2022-12-31) — Current Assets: 1330266.00
GSKR.V balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 0.00
GSKR.V balance_sheet (annual, 2022-12-31) — Current Liabilities: 132497.00
GSKR.V income_statement (annual, 2022-12-31) — Diluted Average Shares: 33273567.00
GSKR.V income_statement (annual, 2022-12-31) — Diluted EPS: -0.04
GSKR.V income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — EBIT: -1664174.00
GSKR.V income_statement (annual, 2022-12-31) — EBITDA: -1664174.00
GSKR.V cash_flow (annual, 2022-12-31) — End Cash Position: 1253348.00
GSKR.V cash_flow (annual, 2022-12-31) — Financing Cash Flow: 2502970.00
GSKR.V cash_flow (annual, 2022-12-31) — Free Cash Flow: -1533824.00
GSKR.V income_statement (annual, 2022-12-31) — Gain On Sale Of Security: -1451.00
GSKR.V balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 6533113.00
GSKR.V income_statement (annual, 2022-12-31) — General And Administrative Expense: 439033.00
GSKR.V income_statement (annual, 2022-12-31) — Interest Income: 0.00
GSKR.V income_statement (annual, 2022-12-31) — Interest Income Non Operating: 0.00
GSKR.V balance_sheet (annual, 2022-12-31) — Invested Capital: 1197770.00
GSKR.V balance_sheet (annual, 2022-12-31) — Investments And Advances: 1.00
GSKR.V balance_sheet (annual, 2022-12-31) — Investmentsin Joint Venturesat Cost: 1.00
GSKR.V cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 2584435.00
GSKR.V balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 1.00
GSKR.V cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 2584435.00
GSKR.V income_statement (annual, 2022-12-31) — Net Income: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -1665625.00
GSKR.V cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -1665625.00
GSKR.V income_statement (annual, 2022-12-31) — Net Interest Income: 0.00
GSKR.V income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 0.00
GSKR.V cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -81465.00
GSKR.V balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 1197770.00
GSKR.V income_statement (annual, 2022-12-31) — Normalized EBITDA: -1662723.00
GSKR.V income_statement (annual, 2022-12-31) — Normalized Income: -1664174.00
GSKR.V cash_flow (annual, 2022-12-31) — Operating Cash Flow: -1533824.00
GSKR.V income_statement (annual, 2022-12-31) — Operating Income: -1664174.00
GSKR.V income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
GSKR.V balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 34323915.00
GSKR.V income_statement (annual, 2022-12-31) — Other Gand A: 439033.00
GSKR.V income_statement (annual, 2022-12-31) — Other Income Expense: -1451.00
GSKR.V income_statement (annual, 2022-12-31) — Other Operating Expenses: 1225141.00
GSKR.V balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 132497.00
GSKR.V balance_sheet (annual, 2022-12-31) — Prepaid Assets: 5417.00
GSKR.V income_statement (annual, 2022-12-31) — Pretax Income: -1665625.00
GSKR.V cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 0.00
GSKR.V balance_sheet (annual, 2022-12-31) — Receivables: 71501.00
GSKR.V balance_sheet (annual, 2022-12-31) — Restricted Cash: 0.00
GSKR.V balance_sheet (annual, 2022-12-31) — Retained Earnings: -16621919.00
GSKR.V income_statement (annual, 2022-12-31) — Salaries And Wages: 0.00
GSKR.V income_statement (annual, 2022-12-31) — Selling General And Administration: 439033.00
GSKR.V balance_sheet (annual, 2022-12-31) — Share Issued: 34323915.00